NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_
On January 10, 2025, NextCure, Inc. (NASDAQ: NXTC) made a significant announcement through a press release, indicating the dosing of the first patient in the Phase 1 study of LNCB74. LNCB74 represents a B7-H4-targeting antibody-drug conjugate (ADC), strategically designed as a therapeutic approach for the treatment of multiple cancers. Dr. Udayan Guha, Senior Vice President […]
More Stories
DOJ Sues Georgia’s Fulton County for Access to 2020 Ballots
By Stacy Robinson The Department of Justice (DOJ) is suing Fulton County, Georgia, to obtain voting records from the 2020...
Machado Plans Venezuela Return, Says Trump’s Pressure Has Weakened Maduro Regime
By Evgenia Filimianova Venezuelan opposition figure and Nobel Peace Prize laureate María Corina Machado has said she plans to return...
Trump Says Thailand, Cambodia Agree to Cease-Fire After Calls With Leaders
By Tom Ozimek President Donald Trump said on Dec. 12 that Thailand and Cambodia had agreed to halt fighting along...
ICE Arrests 2,824, Deports 11,870 in New Orleans in November
By Naveen Athrappully The Immigration and Customs Enforcement (ICE) New Orleans field office arrested 2,824 illegal immigrants in November and...
What to Know About Trump’s New ‘Gold Card’ Visa Program
By Savannah Hulsey Pointer Applications opened on Dec. 10 for the Trump administration’s new Gold Card program that expedites visas...
Watchdog Finds 9 Large US Banks Actively Engaged in Debanking
By Naveen Athrappully Nine of the largest banks have been found to engage in debanking activities, according to preliminary findings...